EP 1317556 A1 20030611 - FUSION PROTEIN FROM ANTIBODY CYTOKINE-CYTOKINE INHIBITOR (SELECTOKINE) FOR USE AS TARGET-SPECIFIC PRODRUG
Title (en)
FUSION PROTEIN FROM ANTIBODY CYTOKINE-CYTOKINE INHIBITOR (SELECTOKINE) FOR USE AS TARGET-SPECIFIC PRODRUG
Title (de)
FUSIONSPROTEIN AUS ANTIKÖRPER-ZYTOKIN-ZYTOKIN INHIBITOR (SELEKTOKIN) ALS ZIELSPEZIFISCHES PRODRUG
Title (fr)
PROTEINE DE FUSION CONSTITUEE D'UN INHIBITEUR D'ANTICORPS-CYTOKINE-CYTOKINE (SELECTOKINE) SERVANT DE PROMEDICAMENT SPECIFIQUE A LA CIBLE
Publication
Application
Priority
- DE 10045592 A 20000915
- EP 0110730 W 20010917
Abstract (en)
[origin: WO0222833A1] Die vorliegende Erfindung betrifft ein Polypeptid mit vorzugsweise antitumoralen und/oder immunmodulierenden Zytokineigenschaften, welches durch Prozessierung <i>in vivo</i> aktivierbar ist, umfassend eine zentrale Region mit spezifischer biologischer Aktivität, an dessen C-terminalem Ende sich eine Region mit einer Prozessierungseinheit und einer Inhibitordomäne befindet, während sich am N-terminalen Ende eine Region befindet, die ein Makromolekül auf einer Zelloberfläche oder eine Komponente der extrazellulären Matrix selektiv erkennt.
[origin: WO0222833A1] The invention relates to a polypeptide having preferably antitumoral and/or immunomodulating cytokine properties which can be activated by processing it <i>in vivo</i>. Said polypeptide comprises a central region that has a specific biological activity. At the C-terminus, said region comprises a region with a processing unit and an inhibitor domain while at its N-terminus it comprises a region that selectively recognizes a macromolecule on a cell surface or a component of the extracellular matrix.
IPC 1-7
C12N 15/62; C07K 19/00; C12N 15/63; C12N 1/21; C12N 5/10; A61K 47/48
IPC 8 full level
A61K 38/00 (2006.01); A61K 47/48 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/525 (2006.01); C07K 14/715 (2006.01); C12N 15/09 (2006.01); C07K 16/18 (2006.01); C07K 16/40 (2006.01); C07K 16/46 (2006.01); C07K 19/00 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12P 21/02 (2006.01)
CPC (source: EP KR US)
A61K 47/6849 (2017.08 - EP US); A61P 35/00 (2018.01 - EP); C07K 14/525 (2013.01 - EP US); C07K 14/7151 (2013.01 - EP US); C07K 16/40 (2013.01 - EP US); C07K 19/00 (2013.01 - KR); C07K 2317/24 (2013.01 - EP US); C07K 2317/622 (2013.01 - EP US); C07K 2319/00 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0222833 A1 20020321; AU 9381901 A 20020326; BG 107613 A 20031231; BR 0113928 A 20030722; CA 2422759 A1 20030317; CN 1214115 C 20050810; CN 1458977 A 20031126; DE 10045592 A1 20020328; EE 200300100 A 20050215; EP 1317556 A1 20030611; HR P20030192 A2 20051031; HU P0301693 A2 20030828; HU P0301693 A3 20051128; IL 154185 A0 20030731; JP 2004508828 A 20040325; KR 20030048041 A 20030618; MX PA03002229 A 20050620; NO 20031185 D0 20030314; NO 20031185 L 20030505; PL 360540 A1 20040906; RU 2003106429 A 20040827; SK 2812003 A3 20031104; US 2004053829 A1 20040318; YU 18903 A 20060525; ZA 200302008 B 20040625
DOCDB simple family (application)
EP 0110730 W 20010917; AU 9381901 A 20010917; BG 10761303 A 20030306; BR 0113928 A 20010917; CA 2422759 A 20010917; CN 01815764 A 20010917; DE 10045592 A 20000915; EE P200300100 A 20010917; EP 01974261 A 20010917; HR P20030192 A 20030314; HU P0301693 A 20010917; IL 15418501 A 20010917; JP 2002527275 A 20010917; KR 20037003738 A 20030314; MX PA03002229 A 20010917; NO 20031185 A 20030314; PL 36054001 A 20010917; RU 2003106429 A 20010917; SK 2812003 A 20010917; US 38043803 A 20030411; YU P18903 A 20010917; ZA 200302008 A 20030312